EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseVergleichsstudie

Comparative Effectiveness of Approved Biologics in Treating Moderate-To-Severe Allergic Asthma: A Systematic Review and Network Meta-Analysis

Yuelu Li, Huan Zong, Mengying Fang, Dan Luo, Xianming Fan

International Archives of Allergy and Immunology · 2025

DOI: 10.1159/000549116 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Archives of Allergy and Immunology, 2025. Verfasst von Yuelu Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China. Hauptthemen laut MEDLINE: Asthma, Biological Products, Anti-Asthmatic Agents. Die Arbeit nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The aim of this study was to conduct a network meta-analysis (NMA) of randomized controlled trials (RCTs) to compare the efficacy of various biologics for treating moderate-to-severe allergic asthma.

Methods

This study conducted a comprehensive and systematic literature search in Cochrane Library, Embase, PubMed, and Web of Science databases from the inception to December 31, 2024. The data extracted from eligible literature were analyzed using the Cochrane Randomized Trials Risk of Bias 2 tool and Stata 18.0 program.

Results

A total of 19 RCTs, involving 7,449 patients with moderate-to-severe allergic asthma, were included in this NMA. In terms of reducing exacerbations, benralizumab (mean difference (MD) = −0.47, 95% confidence interval (CI) [−0.82, −0.12]), dupilumab (MD = −0.47, 95% CI [−0.72, −0.21]), omalizumab (MD = −0.30, 95% CI [−0.42, −0.17]), and tezepelumab (MD = −0.81, 95% CI [−1.09, −0.54]) all demonstrated superior efficacy compared to placebo. Additionally, tezepelumab was markedly more advanced than omalizumab (MD = −0.52, 95% CI [−0.80, −0.23]). With regard to lung function improvement, dupilumab (MD = 0.16, 95% CI [0.07, 0.24]) and tezepelumab (MD = 0.08, 95% CI [0.03, 0.14]) both exceeded placebo. Regarding asthma control, dupilumab (MD = −0.40, 95% CI [−0.77, −0.04]) and omalizumab (MD = −0.49, 95% CI [−0.89, −0.08]) both effectively lowered scores on the asthma control questionnaire (ACQ) compared to placebo. For enhancing quality of life, omalizumab (MD = 0.62, 95% CI [0.21, 1.03]) significantly raised scores on the standardized asthma quality of life questionnaire (AQLQ [S]+12) relative to placebo.

Conclusion

Considering its significant clinical advantages in reducing exacerbations and improving lung function, tezepelumab should be prioritized as a treatment option for moderate-to-severe allergic asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaBiological ProductsAnti-Asthmatic AgentsHumansTreatment OutcomeRandomized Controlled Trials as TopicSeverity of Illness IndexAntibodies, Monoclonal, HumanizedOmalizumab

Stichwörter der Autor:innen

BiologicsEffectivenessModerate-to-severe allergic asthmaNetwork meta-analysisSystematic review

Substanzen

Biological ProductsAnti-Asthmatic AgentsdupilumabAntibodies, Monoclonal, HumanizedOmalizumab

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
  • Inflammation and Allergic Diseases Research Unit, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
  • Department of Respiratory and Critical Care Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China, luodanwy1112@163.com.
  • Inflammation and Allergic Diseases Research Unit, The Affiliated Hospital, Southwest Medical University, Luzhou, China, luodanwy1112@163.com.
  • Laboratory Animal Centre, Model Animal and Human Disease Research of Luzhou Key Laboratory, Southwest Medical University, Luzhou, China, luodanwy1112@163.com.
  • Department of Respiratory and Critical Care Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China, fxm129@163.com.

Zitieren

APA

Li, Y., Zong, H., Fang, M., Luo, D., & Fan, X. (2025). Comparative Effectiveness of Approved Biologics in Treating Moderate-To-Severe Allergic Asthma: A Systematic Review and Network Meta-Analysis. International Archives of Allergy and Immunology. https://doi.org/10.1159/000549116

Vancouver

Li Y, Zong H, Fang M, Luo D, Fan X. Comparative Effectiveness of Approved Biologics in Treating Moderate-To-Severe Allergic Asthma: A Systematic Review and Network Meta-Analysis. International Archives of Allergy and Immunology. 2025. doi:10.1159/000549116

BibTeX
@article{Li2025,
  author = {Li, Yuelu and Zong, Huan and Fang, Mengying and Luo, Dan and Fan, Xianming},
  title = {Comparative Effectiveness of Approved Biologics in Treating Moderate-To-Severe Allergic Asthma: A Systematic Review and Network Meta-Analysis},
  journal = {International Archives of Allergy and Immunology},
  year = {2025},
  doi = {10.1159/000549116}
}
Kostenlos starten →